Data generated by the TCGA research network (http://cancergenome.nih.gov/) indicates that amplification of the IMP2 gene is a relatively common event in comparison to amplification of IMP1 and IMP3 (Figure 1A), occurring in ~35–50% of squamous lung cancers, ~15–27% of ovarian cancers and in 15–20% of head and neck, esophageal, cervical and uterine cancers. This evidence concerns the gene IMP3 and uterine cancer.